



# Market Announcement

29 December 2020

---

## Anteris Technologies Ltd (ASX: AVR) – Suspension from Official Quotation

### Description

The securities of Anteris Technologies Ltd ('AVR') will be suspended from quotation immediately under Listing Rule 17.2, at the request of AVR, pending the release of an announcement regarding a proposed capital package.

### Issued by

**Vanessa Nevjestic**

Adviser, Listings Compliance (Perth)

# ASX ANNOUNCEMENT

29 December 2020

## VOLUNTARY SUSPENSION REQUEST

**Brisbane, Australia and Minneapolis USA**, Anteris Technologies Ltd (ASX: AVR) (**Anteris or the Company**), requests a voluntary suspension be implemented for its ordinary shares (ASX Code: AVR) under Listing Rule 17.2.

Anteris provides the following information for the purposes of Listing Rule 17.2:

- (a) As set out in its request for trading halt dated 19 March 2020, Anteris is currently working on a proposed capital package.
- (b) Anteris has not concluded the terms of the proposed capital package.
- (c) Anteris requests that the voluntary suspension remain in place until Anteris releases an announcement in relation to the outcome of the proposed capital package.
- (d) Anteris is not aware of any reason why the voluntary suspension should not be granted or of any other information necessary to inform the market about the voluntary suspension.

ENDS

### About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT® tissue technology, paired with the unique 3D single piece aortic valve design of DurAVR™, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

### Authorisation and Additional information

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

### For more information:

Ms Kyahn Williamson  
WE Communications  
E: [WE-AUAnterisTech@we-worldwide.com](mailto:WE-AUAnterisTech@we-worldwide.com)  
P: +61 401 018 828  
[www.anteristech.com](http://www.anteristech.com)  
Twitter: @AnterisTech  
Facebook: [www.facebook.com/AnterisTech](http://www.facebook.com/AnterisTech)

### Anteris Technologies Ltd

#### Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

#### Customer Service:

T +61 1300 550 310 | F +61 1300 972 437 | E [info@anteristech.com](mailto:info@anteristech.com) | W [anteristech.com](http://anteristech.com)

Brisbane • Minneapolis • Geneva • Malaga

